Market capitalization | $19.09m |
Enterprise Value | $12.29m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 23.19 |
P/S ratio (TTM) P/S ratio | 36.02 |
P/B ratio (TTM) P/B ratio | 2.39 |
Revenue (TTM) Revenue | $530.00k |
EBIT (operating result TTM) EBIT | $-9.28m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
1 Analyst has issued a forecast Lexaria Bioscience Corp:
1 Analyst has issued a forecast Lexaria Bioscience Corp:
Feb '25 |
+/-
%
|
||
Revenue | 0.53 0.53 |
-
|
|
Gross Profit | 0.44 0.44 |
-
|
|
EBITDA | -9.20 -9.20 |
-
|
EBIT (Operating Income) EBIT | -9.28 -9.28 |
-
|
Net Profit | -9.38 -9.38 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lexaria Bioscience Corp. is a proprietary drug delivery technology company. Its technology DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a tobacco producer for the development of smokeless, oral-based nicotine products. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.
Head office | United States |
CEO | Richard Christopher |
Employees | 7 |
Founded | 2004 |
Website | www.lexariabioscience.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.